{"filing":{"accession_number":"0001171843-26-004406","cik":"0000882361","ticker":"APTOF","company_name":"Aptose Biosciences Inc.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"f8k_063026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184326004406/f8k_063026.htm"},"events":[{"id":15195,"run_id":13562,"accession_number":"0001171843-26-004406","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"The filing discloses the completion of a material acquisition whereby Hanmi Pharmaceutical, through its subsidiary HS North America Ltd., acquired all outstanding common shares of Aptose Biosciences not already owned by Hanmi at C$2.41 per share (a 28% premium). The press release explicitly states \"Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical\" and notes that the arrangement received shareholder approval on March 31, 2026, and final court approval the same date. As a result, Aptose's common shares are expected to be delisted from the TSX, representing a change of control and completion of a material M\u0026A transaction.","company_name":"Aptose Biosciences Inc.","ticker":"APTOF","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12873,"accession_number":"0001171843-26-004406","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses the completion of a material acquisition whereby Hanmi Pharmaceutical, through its subsidiary HS North America Ltd., acquired all outstanding common shares of Aptose Biosciences not already owned by Hanmi at C$2.41 per share (a 28% premium). The press release explicitly states \"Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical\" and notes that the arrangement received shareholder approval on March 31, 2026, and final court approval the same date. As a result, Aptose's common shares are expected to be delisted from the TSX, representing a change of control and completion of a material M\u0026A transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:23:37.505559+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12873,"accession_number":"0001171843-26-004406","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses the completion of a material acquisition whereby Hanmi Pharmaceutical, through its subsidiary HS North America Ltd., acquired all outstanding common shares of Aptose Biosciences not already owned by Hanmi at C$2.41 per share (a 28% premium). The press release explicitly states \"Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical\" and notes that the arrangement received shareholder approval on March 31, 2026, and final court approval the same date. As a result, Aptose's common shares are expected to be delisted from the TSX, representing a change of control and completion of a material M\u0026A transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:23:37.505559+00:00","company_name":"Aptose Biosciences Inc.","ticker":"APTOF","filing_date":"2026-06-30"}]}